Abstract
Background: This study evaluated the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in treatment-naïve adults with HIV-1 and an ultra-high viral load (uVL; HIV-1 RNA ≥500,000 copies/mL)—a population at high risk for suboptimal outcomes.
Methods: A retrospective cohort study was conducted among 75 patients initiating BIC/FTC/TAF. The modified intent-to-treat (mITT) group included all patients, while the per-protocol (PP) group comprised 58 individuals who completed 96 weeks of follow-up. Virological suppression, immunological response, safety, and resistance were assessed.
Results: Virological suppression rates in the PP group were 98.3% at week 48 and 96.6% at week 96, compared to 74.7% and 78.7% in the mITT group—a gap largely due to non-clinical dropouts. Immunological recovery was significant, with median CD4+ counts increasing from 61.5 to 326.0 cells/μL (p < 0.001). No treatment-emergent resistance was detected. Adverse events were mild (6.9%).
Conclusion: BIC/FTC/TAF is highly effective and safe for adherent uVL patients, demonstrating rapid viral suppression and immune recovery. However, real-world effectiveness is significantly limited by socioeconomic barriers, highlighting the need for improved programmatic support to enhance retention and treatment access.
Introduction
Patients presenting with ultra-high viral loads (uVL) represent a high-risk subgroup in HIV care. These individuals face a steeper climb toward virological suppression, a higher risk of developing drug resistance, and faster immunological decline. While clinical trials for the single-tablet regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) have shown excellent results, these trials often exclude or under-represent the most "difficult-to-treat" patients—those with extremely high baseline viral loads or severe opportunistic infections (OIs). This study provides real-world data on how this regimen performs in a highly immunocompromised, treatment-naïve population in China.
Methods and Study Design
Researchers conducted a retrospective cohort study at the Guiyang Public Health Clinical Center, tracking 75 treatment-naïve adults with HIV-1 RNA ≥500,000 copies/mL. The study relied on clinical data from the Chinese AIDS Prevention and Control Database and the hospital's case system. The cohort had a median baseline viral load exceeding 1 million copies/mL and a median CD4+ count of just 61.5 cells/μL, indicating advanced disease.
The study utilized two primary analysis frameworks:
- Modified Intent-to-Treat (mITT): Includes all 75 patients who initiated treatment. In this model, any discontinuation (regardless of reason) is counted as a failure.
- Per-Protocol (PP): Includes only the 58 patients who completed the full 96-week follow-up.
Key Results
Virological Suppression and the "Efficacy-Effectiveness Gap"
The most striking finding is the chasm between how well the drug can work and how it performs in the real world. In the PP group, suppression was 98.3% at Week 48 and 96.6% at Week 96. However, in the mITT group, these rates were significantly lower (74.7% and 78.7%, respectively).
Immunological Recovery and Safety
Immunological recovery was robust, with median CD4+ counts rising from a baseline of 61.5 to 326.0 cells/μL (p < 0.001). Patients also saw a median weight increase of 6.5 kg by week 48, a common marker of returning health in advanced HIV treatment. Adverse events were rare (6.9%) and mild, including dizziness and skin itching; no patients discontinued treatment due to side effects.
Resistance and Early Response
Despite the massive viral presence, zero treatment-emergent resistance was detected over 96 weeks, reinforcing the high genetic barrier of the integrase inhibitor bictegravir. Interestingly, patients presenting with opportunistic infections (OIs) showed higher suppression rates at weeks 12 and 24 compared to those without OIs, possibly due to more intensive clinical monitoring or the synergistic effects of antimicrobial therapies.
Discussion
The risk of "treatment failure" was seven times higher in the mITT group than in the PP group. Crucially, this was not due to medical failure; of the 17 patients who discontinued the study, 11 (64.7%) switched regimens specifically due to economic constraints. This highlights that in real-world settings, the price of a drug is as much a clinical variable as its molecular structure.
While BIC/FTC/TAF is medically ideal for uVL patients, its real-world success is tethered to affordability. The authors call for improved programmatic support—such as subsidies or insurance coverage—to ensure that the most vulnerable patients can maintain access to high-efficacy, single-tablet regimens.
Summary updated